SSSina Seifimansour

Sina Seifimansour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sina Seifimansour has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genistein Exerts Anti-proliferative Effects by Regulating Apoptosis and Autophagy-Related Genes and MicroRNAs in Human Urinary Bladder Neoplasm EJ138 Cells: An Experimental and Bioinformatic Study

    by Alireza Ziyabakhsh, Mohammad Amin Vatankhah, Farid Pakizeh, Ali Nosrat, Pouria Sobhi, Mohammad Vakili Ojarood, Sina Seifimansour

    Background: Bladder cancer (BC) is the most prevalent urogenital malignancy. Recently, the combination of natural compounds with chemotherapeutic agents has gained attention. Genistein, a natural flavonoid, exhibits anti-cancer properties and represents a promising candidate for treating various cancerous cells due to its cytotoxic potential and minimal adverse effects. Objectives: This study aimed to evaluate the anti-cancer effects of genistein by regulating potential target genes and microRNAs involved in apoptosis and autophagy in EJ138 BC cells. Methods: EJ138 BC cells were treated with different concentrations of genistein, and cell viability was assessed using the MTT assay. To determine the apoptotic rate of EJ138 BC cells following genistein treatment, flow cytometry with Annexin V/PI staining was performed. Additionally, real-time PCR was conducted to analyze the expression of miR-27a, miR-151, apoptotic genes (caspase-3, caspase-9), and autophagic genes (ATG12, Beclin1) after 48 hours of genistein treatment. Statistical analysis was carried out using SPSS V.22, with independent t-tests and one-way ANOVA. Results were considered statistically significant at P < 0.05. Results: Our findings demonstrated that genistein inhibited the proliferation, growth, and viability of EJ138 BC cells and induced cell death. Real-time PCR results confirmed that genistein significantly upregulated miR-27a (P < 0.01), ATG12 (P < 0.01), Beclin1 (P < 0.05), caspase-3 (P < 0.001), and caspase-9 (P < 0.0001), while downregulating miR-151 expression (P < 0.05). Conclusions: The results of this study suggest that genistein suppresses the proliferation and growth of human BC cells by modulating genes and microRNAs involved in apoptosis and autophagy. Therefore, genistein may serve as a novel therapeutic agent for BC treatment.


  • Open Access

    Investigation of the impact of iron deficiency anemia on the clinical outcome of hospitalized patients and the 6-month outcome of acute STEMI patients undergoing primary angioplasty

    by Sina Seifimansour, Afshin Moradi, Fatemeh Farahbakhsh, Ahmad Separham, Asal Ebrahimian, Erfan Banisefid, Sana Arcan, Elahe Fattahi, Sina Hamzehzadeh, Elnaz Javanshir

    Background: Acute myocardial infarction (MI), particularly ST-elevation myocardial infarction (STEMI), is a severe form of acute coronary syndrome often resulting from complete coronary artery occlusion. Iron deficiency (ID) is a prevalent nutritional disorder worldwide and may influence cardiovascular outcomes, including in STEMI patients. This study aimed to assess the impact of ID on left ventricular function and clinical outcomes in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Methods: This prospective study included 257 patients with acute STEMI admitted to Shahid Madani hospital in Tabriz between October 2020 and October 2022. Patients who presented within 12 hours of chest pain onset and met the inclusion criteria were categorized into two groups based on the presence or absence of ID, defined by serum ferritin levels <100 mg/dL or transferrin saturation<20%. Comprehensive demographic, clinical, and angiographic data were collected. The primary outcomes assessed were the occurrence of major adverse cardiovascular events (MACE), thrombolysis in myocardial infarction (TIMI) flow grading, and enzymatic infarct size during hospitalization and at 6-month follow-up. Findings: ID was present in 54.4% of the patients. No significant differences were observed between the ID and non-ID groups regarding age, gender, body mass index (BMI), prevalence of comorbidities, or baseline left ventricular ejection fraction (LVEF). Additionally, the incidence of in-hospital and 6-month MACE, TIMI flow after PPCI, and enzymatic infarct size did not differ significantly between the two groups. However, serum iron, transferrin saturation, and ferritin levels were significantly lower in the ID group. Conclusion: Although ID was common among STEMI patients undergoing PPCI, it did not significantly affect in-hospital or 6-month outcomes. These findings suggest that ID may not be a crucial determinant of prognosis in STEMI patients, but further large-scale studies are needed to corroborate these results.


  • Open Access

    Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis

    by Mohammad Amin Akbarzadeh, Yosra Vaez-Gharamaleki, Farid Jahanshahlou, Alireza Ghaffari Bavil, Sina Hamzehzadeh, Sina Seifimansour, Alireza Rahimi-Mamaghani, Mohammad-Salar Hosseini

    Since the beginning of the COVID-19 pandemic, complications of this disease among vulnerable populations have been a primary concern. Cancer patients are among the most vulnerable groups of patients owing to the compromised immune system and weakened overall health status1 1 Akbarzadeh MA, Hosseini MS. Implications for cancer care in Iran during COVID-19 pandemic. Radiother Oncol. 2020;148:148:211-2. https://doi.org/10.1016/j.radonc.2020.04.041 https://doi.org/10.1016/j.radonc.2020.04... .